Positive data from the phase IIa COMBAT clinical trial indicate that CXCR4 and PD-1 blockade with the combination of pembrolizumab (Keytruda) and BL-8040 (motixafortide) can improved upon the benefit of chemotherapy as treatment of pancreatic ductal adenocarcinoma (PDAC).
The COMBAT study (NCT02826486) is one of the first clinical trials to demonstrate a benefit for patients with metastatic pancreatic cancer with immunotherapy, according to the study authors. Read more . . .